1. Inicio
  2. Publicaciones
  3. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.

[Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Munera-Campos M
  • Chicharro P
  • Gonzalez Quesada A
  • Flórez Menéndez Á
  • de la Cueva Dobao P
  • Gimenez Arnau AM
  • Gilaberte Calzada Y
  • Montero-Vilchez T
  • Silvestre JF
  • Elosua-González M
  • Del Alcázar E
  • Santamaría C
  • Sánchez-Pérez J
  • Carretero Hernández G
  • Batalla A
  • Jin Suh Oh H
  • Mauleón Fernández C
  • Curto Barredo L
  • Bertolín-Colilla M
  • Navarro Bielsa A
  • Ballano Ruiz A
  • Arias Santiago S
  • Betlloch I
  • Roustan Gullón G
  • Rosell Díaz A
  • Descalzo MA
  • García-Doval I
  • Carrascosa JM

Grupos

Abstract

BACKGROUND: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential. MATERIALS AND METHOD: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs). RESULTS: We studied data entries for 258 patients who had received 347 systemic treatments for AD. Treatment was discontinued in 29.4% of cases, mostly due to a lack of effectiveness (in 10.7% of cases). A total of 132 AEs were described during follow-up. Eighty-six AEs (65%) were linked to a systemic treatment, most commonly dupilumab (39 AEs) and cyclosporine (38 AEs). The most common AEs were conjunctivitis (11 patients), headache (6), hypertrichosis (5), and nausea (4). There was 1 severe AE (acute mastoiditis) associated with cyclosporine. CONCLUSIONS: Initial findings on AEs from the Spanish BIOBADATOP registry are limited by short follow-up times precluding comparisons or calculation of crude and adjusted incidence rates. At the time of our analysis, no severe AEs had been reported for novel systemic therapies. BIOBADATOP will help answer questions on the effectiveness and safety of conventional and novel systemic therapies in AD.

Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
479-487
PubMed:
37172898
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 4

Citas Recibidas en Scopus: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acontecimientos adversos; Adverse events; Atopic dermatitis; Biologics; Biológicos; Dermatitis atópica; Inhibidores de JAK; JAK inhibitors; Registries; Registro prospectivo; Tratamientos; Treatments

Compartir